Abstract

BackgroundAntibiotics are overused in patients hospitalized with acute respiratory illness (ARI). Diagnostic uncertainty regarding microbial etiology contributes to this practice and so a host response test that can distinguish between viral and bacterial infection has the potential to reduce unnecessary antibiotic use. The FebriDx is a low cost, rapid, host response POCT that uses fingerpick blood samples to distinguish between viral and bacterial infection but has not been evaluated in hospitalized adults with ARI.MethodsWe took fingerpick blood samples from adult patients with ARI, hospitalized during influenza season, and tested them on the FebriDx. Respiratory samples were tested for viruses on the FilmArray Respiratory Panel (FARP). The FebriDx was evaluated for ease of use, failure rate and accuracy of the results (Viral, Bacterial, Negative).Results149 patients were approached and 10 patients declined fingerpick testing. A valid result was obtained from 124/139 (89%) overall. Common user comments included test failure due to difficulty of getting blood to fill the capillary tube and difficulty in interpreting the results lines due to the variability of color change. 111/124 (89%) were tested for viruses by FARP. 69/111 (62%) had viruses detected. Of 69 patients with viruses detected, 41 (59%) had influenza, 12 (17%) rhino/enterovirus and 16 (23%) other viruses. 44/69 (64%) had a viral FebriDx result. For influenza-positive patients 34/41 (83%) had a viral FebriDx result, 1/12(8%) of rhinovirus-positive patients had a viral FebriDx result and 9/16 (56%) of patients with other viruses detected had a viral FebriDx result. These are interim results. Full results for 200 patients will be available at presentation.ConclusionThe use of the FebriDx POC was associated with a failure rate of ~10% and problems with the interpretation of result lines. FebriDx was not sufficiently accurate in differentiating viral and bacterial infection when using detection of virus by PCR as the definition of viral infection; however, FebriDx had a high PPV for all viral detection and for influenza detection in this cohort and could have utility in hospital emergency departments. Disclosures All authors: No reported disclosures.

Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.